Iris Isufi, MD
Research & Publications
Biography
News
Extensive Research Description
Dr. Isufi's clinical work has been in the area of hematologic malignancies and autologous and allogeneic stem cell transplantation for these conditions. As part of the lymphoid malignancy and transplant teams, she developed a strong clinical interest in aggressive lymphomas. She has focused her efforts in treating patients with aggressive lymphomas as part of clinical trials and consolidating their response to treatment with either autologous or allogeneic transplant based on specifics of their disease. She has a research interest in early drug development in lymphoma, and has served as local PI for a variety of industry- and cooperative-group-sponsored lymphoma trials, including phase 1 trials.
Coauthors
Research Interests
Clinical Trials as Topic; Graft vs Host Disease; Lymphoma; Bone Marrow Transplantation; Clinical Trials, Phase I as Topic; Transplantation Conditioning
Selected Publications
- Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphomaHalwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, JH T, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma Leukemia & Lymphoma 2021, 63: 821-833. PMID: 34865586, DOI: 10.1080/10428194.2021.2010057.
- Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinibHolowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.
- Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusionPerreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion American Journal Of Health-System Pharmacy 2021, 78: zxab072. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
- Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.
- Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphomaPatel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
- Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomasIsufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
- Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on RuxolitinibFoss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
- Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience* Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
- The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN) Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
- Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantationKim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
- Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell LymphomaCyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
- Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administrationPerreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.
- The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHDNadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.
- Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular CarcinomaSaif MW, Isufi I, Peccerillo J, Syrigos KN. Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma Gastroenterology Research And Practice 2011, 2011: 616080. PMID: 21687621, PMCID: PMC3113260, DOI: 10.1155/2011/616080.
- Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13 Rheumatology 2010, 50: 824-829. PMID: 21149242, DOI: 10.1093/rheumatology/keq395.
- Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Research 2010, 30: 2927-33. PMID: 20683034.
- Transforming Growth Factor- Signaling in Normal and Malignant HematopoiesisIsufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, Pahanish P, Verma A. Transforming Growth Factor- Signaling in Normal and Malignant Hematopoiesis Journal Of Interferon & Cytokine Research 2007, 27: 543-552. PMID: 17651015, DOI: 10.1089/jir.2007.0009.